A Phase III trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer demonstrated no survival benefit.
The post Rova-T programme discontinued following poor trial results appeared first on European Pharmaceutical Review.
Original Article: Rova-T programme discontinued following poor trial results